Literature DB >> 28124634

Buspirone for the treatment of dementia with behavioral disturbance.

Maria R Santa Cruz1, Priscilla C Hidalgo1, Meredith S Lee1, Cornelius W Thomas2, Suzanne Holroyd2.   

Abstract

Behavioral disturbances are common but serious symptoms in patients with dementia. Currently, there are no FDA approved drugs for this purpose. There have been case reports and small case series of the use of buspirone. In this retrospective study, we review 179 patients prescribed buspirone for treatment of behavioral disturbance in dementia to better characterize the efficacy and potential side effects. All patients prescribed buspirone for behavioral disturbance due to dementia from a geropsychiatric outreach program were reviewed. Data was collected and analyzed using SPSS. One hundred-seventy-nine patients met criteria for the study with a mean age of 83.8 + 7. Alzheimer's dementia was the most common dementia (n = 61; 34.1%) followed by mixed dementia (n = 50, 27.9%) then vascular type (n = 31; 17.3%). Behavioral disturbances were mainly verbal aggression (n = 125; 69.8%), and physical aggression (n = 116; 64.8%). Using the Clinical Global Impression scale, 68.6% of patients responded to buspirone, with 41.8% being moderately to markedly improved. The mean dose of buspirone was 25.7 mg ± 12.50. Buspirone appears to be effective in treating behavioral disturbances in dementia. Future prospective and double blinded studies are needed.

Entities:  

Keywords:  Alzheimer's; behavioral disturbance; buspirone; dementia

Mesh:

Substances:

Year:  2017        PMID: 28124634     DOI: 10.1017/S1041610216002441

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  4 in total

1.  Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo.

Authors:  Bo-Wen Zhang; Ni-Hong Pang; Ren-Ai Xu; Gao-Er Qu; Cong-Rong Tang
Journal:  Drug Des Devel Ther       Date:  2022-06-30       Impact factor: 4.319

2.  Pharmacologic Management of Agitation in Patients with Dementia.

Authors:  Cara L McDermott; David A Gruenewald
Journal:  Curr Geriatr Rep       Date:  2019-01-22

Review 3.  The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions.

Authors:  Rachel M Keszycki; Daniel W Fisher; Hongxin Dong
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

4.  Gender Differences in Demographic and Pharmacological Factors in Patients Diagnosed with Late-Onset of Alzheimer's Disease.

Authors:  Melissa J Bailey-Taylor; Nicolas Poupore; Laurie Theriot Roley; Richard L Goodwin; Brooks Mcphail; Thomas I Nathaniel
Journal:  Brain Sci       Date:  2022-01-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.